For the ANCOVA model, the group getting 80 mg of atorvastatin plus SAR236553 was weighed against the group receiving 80 mg of atorvastatin plus placebo, and the 95 percent confidence interval of the difference was calculated. For secondary analyses or end factors, P values have already been supplied for descriptive reasons only and have not been altered for multiple testing. Although formal comparisons with the group receiving 10 mg of atorvastatin plus SAR236553 were not planned, these were performed post hoc for descriptive purposes.The %ages of patients who had been 10 to 11 years of age were 33.9 percent, 31.8 percent, and 23.4 percent in the four-dose group, the two-dose group, and the placebo group, respectively, whereas the corresponding %ages for patients 16 to 20 years of age were 18.3 percent, 11.2 percent, and 21.6 percent; for the 12-to-15-year age group, the %ages were 47.7 percent, 57.0 percent, and 55.0 percent, respectively. Prespecified Efficacy End Factors Stimulated C-peptide levels demonstrated a progressive decline from baseline to month 15 in every three study groups . As demonstrated in Table 2Table 2Prespecified Efficacy Outcomes, According to Study Group., at 15 weeks, the treatment effect of the four-dose and two-dosage regimens combined was not significantly larger than the effect of placebo .